2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects.

      Eye & Contact Lens

      Adult, Aged, Aged, 80 and over, Combined Modality Therapy, methods, Contact Lenses, Hydrophilic, Corneal Diseases, pathology, therapy, Epithelium, Corneal, Female, Humans, Hydrogel, Male, Middle Aged, Ophthalmic Solutions, therapeutic use, Serum, Silicones

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We investigated the utility of a combination of autologous serum eye drops and a silicone-hydrogel (SH) lens in the treatment of persistent epithelial defects (PEDs). Eight patients who had distinct PED conditions were treated with 50% (v/v) autologous serum eye drops in combination with silicone hydrogel contact lenses and prospectively observed. The pathogenesis of PEDs included Sjogren-type dry eye syndrome, graft-versus-host disease, toxic keratitis, limbal cell deficiency, superior limbic keratoconjunctivitis, and neurotrophic keratitis. The patients had PEDs for 90±81.76 days (range: 30-240 days). Before the initiation of the combined treatment, three patients had already been unsuccessfully treated with SH lenses, and five patients had received serum eye drops alone. The PEDs of the eight eyes healed after a treatment period of 11.8±4.9 days. No visible deposits were noted on the surface of any contact lens. These findings demonstrate that the combination of an SH lens and serum eye drops may be effective in the treatment of intractable PEDs.

          Related collections

          Author and article information

          Journal
          21983552
          10.1097/ICL.0b013e318233c9bb

          Comments

          Comment on this article